Printer Friendly

IMMUNOMEDICS REPORTS BENEFITS OF COLORECTAL CANCER IMAGING AGENT

 IMMUNOMEDICS REPORTS BENEFITS OF COLORECTAL CANCER IMAGING AGENT
 WARREN, N.J., March 6 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) today presented the results of the company's pivotal Phase III clinical studies, describing the benefits of its colorectal cancer imaging agent, ImmuRAID(TM)-CEA, at the International Conference on Monoclonal Antibody Immunoconjugates for Cancer in San Diego.
 In 35 percent of the patients with ImmuRAID-CEA, new or additional information about the disease was provided, changing the method of treatment for patients in these clinical trials.
 ImmuRAID-CEA clinical results have indicated that this product is rapid and easy to use and can detect tumors missed by conventional techniques and also appropriately did not disclose (true negative) tumors which had incorrectly been classified as tumors by other methods. This Phase III clinical trial data was included in the company's Product License Application (PLA) which was submitted to the U.S. Food and Drug Administration in April 1991.
 "ImmuRAID-CEA has detected tumors as small as an eighth of an inch and has demonstrated the ability to image the liver. Imaging this vital organ is important because the liver is often the first site that colorectal cancer will spread. ImmuRAID-CEA may provide earlier and more accurate diagnosis which will afford patients the opportunity to receive the most appropriate treatment," noted Dr. Carl Pinsky, vice president, medical affairs. "In our clinical studies, there has been virtually no allergic human anti-mouse antibody (HAMMA) response in ImmuRAID-CEA patients because ImmuRAID-CEA, as well as all of Immunomedics' imaging agents, consist of a monoclonal antibody fragment directly labeled with the low-cost radioisotope technetium-99m," further noted Pinsky.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections.
 -0- 3/6/92
 /CONTACT: Joseph Schepers of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


CK-AH -- NY037 -- 5909 03/06/92 13:51 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 6, 1992
Words:346
Previous Article:VANCOUVER MARKET MAINTAINS MOMENTUM
Next Article:SMALLER INCISIONS, SHORTER RECOVERY TIME WITH NEW ALTERNATIVE TO TRADITIONAL SURGERY
Topics:


Related Articles
IMMUNOMEDICS REPORT NEW RESULTS OF LUNG CANCER AND LYMPHOMA IMAGING AGENTS
IMMUNOMEDICS REPORTS VIRTUALLY NO ALLERGIC REACTIONS IN PATIENTS IMAGED WITH ANTIBODY AGENT, IMMURAID-CEA
IMMUNOMEDICS' COLORECTAL CANCER DETECTION AGENT ACCLAIMED AT SURGICAL CONGRESS: FINDINGS SHOW ACCURACY OF OVER 90 PERCENT
IMMUNOMEDICS REPORTS RESULTS WITH INFECTIOUS DISEASE IMAGING AGENT
IMMUNOMEDICS REPORTS ON REPEAT USAGEOF COLORECTAL CANCER DETECTION AGENT
IMMUNOMEDICS REPORTS ON POTENTIAL DIAGNOSTIC FOR AIDS-RELATED PNEUMONIA
IMMUNOMEDICS AWARDED ORPHAN DRUG DESIGNATION FOR CEA-SCAN IN THE DIAGNOSIS OF MEDULLARY THYROID CANCER
IMMUNOMEDICS' CEA-SCAN IDENTIFIED COLORECTAL CANCER IN 61% OF PATIENTS IN WHOM CONVENTIONAL TESTS FAILED
NEW CANCER DETECTION AGENT CLEARED BY FDA
Immunomedic Engages Lehman Brothers As Financial Advisor

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters